When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Queloide

Última revisão: 4 Feb 2025
Última atualização: 08 Oct 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • história de evento incitante (por exemplo, piercing, cirurgia, vacinação)
  • crescimento lento/ausência de regressão espontânea
  • cicatriz elevada, eritematosa, lisa e brilhante com borda saliente
Detalhes completos

Outros fatores diagnósticos

  • prurido ou dor
Detalhes completos

Fatores de risco

  • história anterior de queloide
  • tensão local na pele
  • inflamação/infecção folicular
  • história familiar de queloide e fatores genéticos
  • tipos de pele escura
  • Estado hormonal
  • doenças sistêmicas (por exemplo, hipertensão, eczema atópico, doença de Castleman)
  • fatores de estilo de vida
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • diagnóstico clínico
Detalhes completos

Investigações a serem consideradas

  • biópsia de pele
Detalhes completos

Algoritmo de tratamento

AGUDA

queloide pequeno/único

queloides grandes/volumosos/múltiplos

Colaboradores

Autores

Ioannis Goutos, FRCSEd(Plast)

Consultant Plastic Surgeon

Director of Academic Plastic Surgery Programmes

Queen Mary University of London

London

UK

Declarações

IG is an author of a number of references cited in this topic.

Richard Shaffer, MRCP, FRCR

Consultant Clinical Oncologist

GenesisCare

Cromwell Hospital

London

UK

Declarações

RS wrote the radiotherapy section of this topic. At the time of writing, he had received funds as a consultant as clinical lead for GenesisCare for skin and benign radiotherapy and as medical director for XStrahl, which designs and manufactures radiotherapy machines that can be used to treat keloid scars. RS has spoken at educational events on radiotherapy for keloid scarring and other benign and malignant conditions and has a working relationship with plastic surgeons who refer patients for radiotherapy for keloid scarring.Since contributing to the topic, RS has declared that he treats patients with radiotherapy for keloid scars in the private sector for GenesisCare and has received consulting fees from GenesisCare. He is also reimbursed for being a medical director and a shareholder and board member of Xstrahl Limited. He is board member and president of International Organisation for Radiotherapy for Benign Conditions (a community interest company), and has given webinars on the topic of radiotherapy for keloid scars for them. He is director and chief medical officer of Theralife, a company formed to treat patients with radiotherapy for non-cancer conditions. He works clinically with Ioannis Goutos for the benefit of patients with keloid scars. RS will not make further contributions to this topic.

Agradecimentos

Mr Ioannis Goutos and Dr Richard Shaffer would like to gratefully acknowledge Professor Andrew Burd, and Dr Lin Huang, previous contributors to this topic.

Declarações

AB and LH are authors of a number of references cited in this topic.

Revisores

Edward E. Tredget, MD, MSc, FRCSC

Director

Firefighters' Burn Treatment Unit and Plastic Surgery Wound Healing Research Laboratory

Professor

Department of Surgery

University of Alberta

Edmonton

Alberta

Canada

Declarações

EET declares that he has no competing interests.

Boni E. Elewski, MD

Professor and Chair of Dermatology

University of Alabama

Birmingham

AL

Declarações

BEE declares that she has no competing interests for this topic.

  • Queloide images
  • Diagnósticos diferenciais

    • Cicatriz hipertrófica
    • Dermatofibrossarcoma protuberante
    • Dermatofibroma
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Recommendations for using radiotherapy for benign disease in the UK: keloid scarring
    • S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids)
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal